Abstract
Biomarkers have revolutionized cancer chemotherapy. However, many biomarker candidates are still in debate. In addition to clinical studies, a priori experimental approaches are needed. Thymidylate synthase (TS) expression is a long-standing candidate as a biomarker for 5-fluorouracil (5-FU) treatment of cancer patients. Using the Tet-OFF system and a human colorectal cancer cell line, DLD-1, we first constructed an in vitro system in which TS expression is dynamically controllable. Quantitative assays have elucidated that TS expression in the transformant was widely modulated, and that the dynamic range covered 15-fold of the basal level. 5-FU sensitivity of the transformant cells significantly increased in response to downregulated TS expression, although being not examined in the full dynamic range because of the doxycycline toxicity. Intriguingly, our in vitro data suggest that there is a linear relationship between TS expression and the 5-FU sensitivity in cells. Data obtained in a mouse model using transformant xenografts were highly parallel to those obtained in vitro. Thus, our in vitro and in vivo observations suggest that TS expression is a determinant of 5-FU sensitivity in cells, at least in this specific genetic background, and, therefore, support the possibility of TS expression as a biomarker for 5-FU-based cancer chemotherapy.
Highlights
Biomarkers predicting patient outcomes play an essential role in various medical fields, in target-based cancer therapies
Establishment of a human colorectal cancer cell line expressing TYMS transgene variably The expression vector carrying the Kozak-modified TYMS cDNA, pTRE2hyg-TS3 (Fig 1B), and pTet-ON/OFF vectors were co-transfected into a human colorectal cancer cell line, DLD-1 (Fig 1C)
Numerous clinical studies have been done on Thymidylate synthase (TS) expression in human cancers, in order to clarify its significance as a determinant of 5-FU sensitivity of tumors
Summary
Biomarkers predicting patient outcomes play an essential role in various medical fields, in target-based cancer therapies. Biomarkers are regarded as reflecting the structural and functional states of target molecules and those functioning up/downstream of them. According to the status of biomarkers, patients are stratified and treated in several neoplastic diseases. The accuracy of prediction is not yet satisfactory in general. In many of the target molecules, their roles in drug sensitization are not well.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.